Quarterly Investor Update - Q2 FY23 Test Volumes rise 36%

GENERAL

Mon, Oct 17 2022 09:26 am

Our announcement posted this morning at 8.56am was intended to be marked with a P flag.

QUARTERLY INVESTOR UPDATE – Q2 FY23 TEST VOLUMES RISE 36% ON Q2 FY22
DUNEDIN, New Zealand -- Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) has today released its September Quarter Shareholder Update (attached) showing early signs that its investment in US sales and marketing initiatives are driving the adoption of its advanced genomic biomarker Cxbladder tests.

In the three months to the end of September (Q2 FY23) total test volumes processed in the company’s laboratories were 7,861 up 36% on the 5,780 tests processed in the same quarter of the prior year and up 11% on the 7,055 tests processed in the three months to the end of June 2022 (Q1 FY23). Volumes for the quarter are 36% more than the average volumes recorded in the 2022 financial year.

For the six months to the end of September 2022, Pacific Edge processed 14,916 tests in its laboratories, a figure that represents a 34% increase on the 11,136 tests processed in the same period in the prior financial year.

Further detail on test volumes is covered in the shareholder update.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.   

For more information:

Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: 021 645 643
P: 022 032 1263

OVERVIEW www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder www.cxbladder.com
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy.

Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the test online.